BNT113
HPV16+ head and neck cancer
Key Facts
About BioNTech
BioNTech SE is a pioneering German biotechnology company founded in 2008 with a mission to translate immunological science into life-saving immunotherapies and vaccines. Its historic achievement was the co-development and global commercialization of the first approved mRNA-based COVID-19 vaccine, Comirnaty, with Pfizer, which validated its core platform and provided substantial financial and operational resources. The company is now strategically deploying its validated mRNA technology, alongside complementary modalities like bispecific antibodies, to build a deep and diversified oncology pipeline while advancing next-generation vaccines for infectious diseases.
View full company profile